144 related articles for article (PubMed ID: 32400847)
21. Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding.
Cagnoni AJ; Kovensky J; Uhrig ML
J Org Chem; 2014 Jul; 79(14):6456-67. PubMed ID: 24937526
[TBL] [Abstract][Full Text] [Related]
22. The therapeutic potential of galectin-3 inhibition in fibrotic disease.
Slack RJ; Mills R; Mackinnon AC
Int J Biochem Cell Biol; 2021 Jan; 130():105881. PubMed ID: 33181315
[TBL] [Abstract][Full Text] [Related]
23. Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.
Zetterberg FR; MacKinnon A; Brimert T; Gravelle L; Johnsson RE; Kahl-Knutson B; Leffler H; Nilsson UJ; Pedersen A; Peterson K; Roper JA; Schambye H; Slack RJ; Tantawi S
J Med Chem; 2022 Oct; 65(19):12626-12638. PubMed ID: 36154172
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 in Cardiovascular Diseases.
Blanda V; Bracale UM; Di Taranto MD; Fortunato G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287402
[TBL] [Abstract][Full Text] [Related]
25. Carbohydrate triazoles and isoxazoles as inhibitors of galectins-1 and -3.
Giguère D; Patnam R; Bellefleur MA; St-Pierre C; Sato S; Roy R
Chem Commun (Camb); 2006 Jun; (22):2379-81. PubMed ID: 16733586
[TBL] [Abstract][Full Text] [Related]
26. Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins.
Sethi A; Sanam S; Alvala M
Eur J Med Chem; 2021 Oct; 222():113561. PubMed ID: 34146913
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of a Xenopus laevis skin proto-type galectin, close to but distinct from galectin-1.
Nonaka Y; Ogawa T; Yoshida H; Shoji H; Nishi N; Kamitori S; Nakamura T
Glycobiology; 2015 Jul; 25(7):792-803. PubMed ID: 25804418
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship of Citrus segment membrane RG-I pectin against Galectin-3: The galactan is not the only important factor.
Wu D; Zheng J; Hu W; Zheng X; He Q; Linhardt RJ; Ye X; Chen S
Carbohydr Polym; 2020 Oct; 245():116526. PubMed ID: 32718630
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of a phenyl thio-beta-D-galactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: discovery of efficient and selective monosaccharide inhibitors of galectin-7.
Cumpstey I; Carlsson S; Leffler H; Nilsson UJ
Org Biomol Chem; 2005 May; 3(10):1922-32. PubMed ID: 15889175
[TBL] [Abstract][Full Text] [Related]
30. Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
van Hattum H; Branderhorst HM; Moret EE; Nilsson UJ; Leffler H; Pieters RJ
J Med Chem; 2013 Feb; 56(3):1350-4. PubMed ID: 23281927
[TBL] [Abstract][Full Text] [Related]
31. C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions.
Cumpstey I; Sundin A; Leffler H; Nilsson UJ
Angew Chem Int Ed Engl; 2005 Aug; 44(32):5110-2. PubMed ID: 16007713
[No Abstract] [Full Text] [Related]
32. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
33. Inhibition and detection of galectins.
Pieters RJ
Chembiochem; 2006 May; 7(5):721-8. PubMed ID: 16566049
[TBL] [Abstract][Full Text] [Related]
34. Research progress on the role of gal-3 in cardio/cerebrovascular diseases.
Cao ZQ; Yu X; Leng P
Biomed Pharmacother; 2021 Jan; 133():111066. PubMed ID: 33378967
[TBL] [Abstract][Full Text] [Related]
35. Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.
Rauthu SR; Shiao TC; André S; Miller MC; Madej É; Mayo KH; Gabius HJ; Roy R
Chembiochem; 2015 Jan; 16(1):126-39. PubMed ID: 25407851
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9 N-terminal carbohydrate recognition domain.
Nagae M; Nishi N; Murata T; Usui T; Nakamura T; Wakatsuki S; Kato R
Glycobiology; 2009 Feb; 19(2):112-7. PubMed ID: 18977853
[TBL] [Abstract][Full Text] [Related]
37. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
38. Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology.
Laaf D; Bojarová P; Elling L; Křen V
Trends Biotechnol; 2019 Apr; 37(4):402-415. PubMed ID: 30413271
[TBL] [Abstract][Full Text] [Related]
39. Soluble beta-galactosyl-binding lectin (galectin) from toad ovary: crystallographic studies of two protein-sugar complexes.
Bianchet MA; Ahmed H; Vasta GR; Amzel LM
Proteins; 2000 Aug; 40(3):378-88. PubMed ID: 10861929
[TBL] [Abstract][Full Text] [Related]
40. The association between oxidative stress-induced galectins and differentiation of human promyelocytic HL-60 cells.
Vinnai JR; Cumming RC; Thompson GJ; Timoshenko AV
Exp Cell Res; 2017 Jun; 355(2):113-123. PubMed ID: 28365246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
